WO2001092876A3 - Verfahren zur identifizierung von verbindungen zur modulierung der aktivität eines tumorsuppressorproteins - Google Patents

Verfahren zur identifizierung von verbindungen zur modulierung der aktivität eines tumorsuppressorproteins Download PDF

Info

Publication number
WO2001092876A3
WO2001092876A3 PCT/EP2001/005842 EP0105842W WO0192876A3 WO 2001092876 A3 WO2001092876 A3 WO 2001092876A3 EP 0105842 W EP0105842 W EP 0105842W WO 0192876 A3 WO0192876 A3 WO 0192876A3
Authority
WO
WIPO (PCT)
Prior art keywords
activity
modulating
identifying compounds
tumour suppressor
suppressor protein
Prior art date
Application number
PCT/EP2001/005842
Other languages
English (en)
French (fr)
Other versions
WO2001092876A2 (de
Inventor
Helen Morrison
Helmut Ponta
Peter Herrlich
Original Assignee
Karlsruhe Forschzent
Helen Morrison
Helmut Ponta
Peter Herrlich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karlsruhe Forschzent, Helen Morrison, Helmut Ponta, Peter Herrlich filed Critical Karlsruhe Forschzent
Priority to US10/296,424 priority Critical patent/US20040072171A1/en
Priority to JP2002501032A priority patent/JP2003535336A/ja
Priority to EP01943423A priority patent/EP1285270A2/de
Publication of WO2001092876A2 publication Critical patent/WO2001092876A2/de
Publication of WO2001092876A3 publication Critical patent/WO2001092876A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Identifizierung von Verbindungen, welche die Aktivität des intrazellulären Tumorsuppressorgens nf2 verändern, wobei durch eine extrazelluläre Wechselwirkung der Verbindungen mit dem Zelloberflächenprotein CD44 das durch das Gen nf2 kodierte Protein NF2 in seiner Aktivität verändert wird.
PCT/EP2001/005842 2000-05-30 2001-05-22 Verfahren zur identifizierung von verbindungen zur modulierung der aktivität eines tumorsuppressorproteins WO2001092876A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/296,424 US20040072171A1 (en) 2000-05-30 2001-05-22 Method for identifying compounds for modulating the activity of a tumor suppressor protein
JP2002501032A JP2003535336A (ja) 2000-05-30 2001-05-22 腫瘍サプレッサータンパク質の活性を調節するための化合物の同定法
EP01943423A EP1285270A2 (de) 2000-05-30 2001-05-22 Verfahren zur identifizierung von verbindungen zur modulierung der aktivität eines tumorsuppressorproteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10026833A DE10026833A1 (de) 2000-05-30 2000-05-30 Verfahren zur Identifizierung von Verbindungen zur Modulierung der Aktivität eines Tumorsuppressorgens
DE10026833.1 2000-05-30

Publications (2)

Publication Number Publication Date
WO2001092876A2 WO2001092876A2 (de) 2001-12-06
WO2001092876A3 true WO2001092876A3 (de) 2002-06-20

Family

ID=7644128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005842 WO2001092876A2 (de) 2000-05-30 2001-05-22 Verfahren zur identifizierung von verbindungen zur modulierung der aktivität eines tumorsuppressorproteins

Country Status (5)

Country Link
US (1) US20040072171A1 (de)
EP (1) EP1285270A2 (de)
JP (1) JP2003535336A (de)
DE (1) DE10026833A1 (de)
WO (1) WO2001092876A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110904051B (zh) * 2019-12-26 2021-08-06 上海交通大学医学院附属第九人民医院 人源听神经瘤永生化细胞系、制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506119A (en) * 1990-05-07 1996-04-09 Kernforschungszentrum Karlsruhe Gmbh DNA encoding variant CD44 surface proteins associated with metastatic tumors
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024913A1 (en) * 1994-03-14 1995-09-21 The General Hospital Corporation Treatment of graft-versus-host disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506119A (en) * 1990-05-07 1996-04-09 Kernforschungszentrum Karlsruhe Gmbh DNA encoding variant CD44 surface proteins associated with metastatic tumors
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAJORATH JURGEN: "Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions.", PROTEINS, vol. 39, no. 2, 1 May 2000 (2000-05-01), pages 103 - 111, XP001053566, ISSN: 0887-3585 *
GUSELLA JAMES F ET AL: "Merlin: The neurofibromatosis 2 tumor suppressor.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1423, no. 2, 25 March 1999 (1999-03-25), pages M29 - M36, XP001053528, ISSN: 0006-3002 *
HERRLICH PETER ET AL: "CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 910, 2000, Conference on Colorectal Cancer New Aspects of Molecular Bioloogy, Immunology and Clinical Applications;Berlin, Germany; October 08-09, 1999, aspects of molecular biology and immunology and their clin, pages 106 - 120, XP001053547, ISBN: 1-57331-277-0 *
MORRISON HELEN ET AL: "The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.", GENES & DEVELOPMENT, vol. 15, no. 8, 15 April 2001 (2001-04-15), pages 968 - 980, XP002190162, ISSN: 0890-9369 *

Also Published As

Publication number Publication date
US20040072171A1 (en) 2004-04-15
EP1285270A2 (de) 2003-02-26
WO2001092876A2 (de) 2001-12-06
JP2003535336A (ja) 2003-11-25
DE10026833A1 (de) 2001-12-13

Similar Documents

Publication Publication Date Title
WO2002024865A3 (en) Modulation of secondary metabolite production by zinc binuclear cluster proteins
EP1180371A4 (de) WIRKSTOFFE ZUR FöRDERUNG DER AUSBILDUNG EINER MEMBRAN ALS HAUTGRUNDLAGE, WIRKSTOFFE ZUR FöRDERUNG DER AUSBILDUNG VON KüNSTLICHER HAUT UND VERFAHREN ZUR HERSTELLUNG VON KüNSTLICHER HAUT
IL150168A0 (en) Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods bsed thereon
WO2003062375A3 (en) Stabilizing polypeptides which have been exposed to urea
WO2002090600A3 (en) A method for regulating immune function in primates using the foxp3 protein
WO1999043830A3 (en) Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2003012082A3 (en) Method for modulating stem cell differentiation using stem loop rna
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
WO2002077263A3 (en) Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
WO2002092841A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
WO2002077267A3 (en) Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
WO2000053737A3 (en) Mitomycin biosynthetic gene cluster
WO2001059153A3 (de) Verfahren zur identifizierung von substanzen, die die aktivität von hyperpolarisations-aktivierten kationen-kanälen modulieren
WO2004074448A3 (en) mTOR KINASE-ASSOCIATED PROTEINS
WO2002066045A3 (en) Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
WO2001092876A3 (de) Verfahren zur identifizierung von verbindungen zur modulierung der aktivität eines tumorsuppressorproteins
WO2001072328A3 (en) Methods of treating diseases with activated protein c
EP1211313A3 (de) Modulation der PDE11A-AKtivität
WO2003087054A3 (en) Methods for identifying compounds that modulate enzymatic activity
TW200510460A (en) Antimicrobial polypeptides
AU2003211040A1 (en) The eaat2 promoter and uses thereof
WO2003051314A3 (en) Antibiotic compounds
MXPA03007694A (es) Polinucleotido util para modular la proliferacion de celulas cancerosas.
WO1998046768A3 (en) Phenolic acid esterase and use thereof
HK1049026A1 (zh) L-薄荷醇的製備方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2001943423

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 501032

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001943423

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10296424

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001943423

Country of ref document: EP